Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
This webinar will present the OUD Cascade of Care, explain how to create one for your program and use it to evaluate and sustain your MOUD continuum of care.
Learning Objectives:
Understand the cascade of care for opioid use disorder (OUD)
Define metrics for your OUD cascade of care
Use the cascade of care to take action that improves sustainability
Target Audience: Implementation I, Implementation II, MAT Expansion, but all cohorts are welcome
Posted 10/27/2021 (updated 4/3/2024)
Posted 7/3/2023 (updated 3/28/2024)
The Bureau of Justice Assistance and the National Institute of Corrections published the Guidelines for Managing Substance Withdrawal in Jails: A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals to help increase access to evidence-based treatment for individuals with SUD and those who are at risk for overdose. There is a high prevalence of SUD among individuals who are incarcerated. Withdrawal while incarcerated is less discussed, but still poses a risk for individuals. The guidelines were created to help jail administrators protect the health and rights of people incarcerated.
Posted 11/28/2023 (updated 3/28/2024)
Substance use is a major health issue among individuals in custody, and for these individuals, withdrawal from substances can be life-threatening. Jurisdictions have a pressing responsibility to save lives by implementing policies and protocol that align with legal, regulatory, and clinical standards related to appropriate withdrawal management. Recently released Guidelines for Managing Substance Withdrawal in Jails sets forth best clinical practices and actionable guidance for jails. This presentation discussed readiness for implementation, key components of implementation, and solutions for implementation in local communities and jails.
Learning Objectives:
-Assessed readiness for implementing a comprehensive and appropriate multidisciplinary approach to withdrawal management.
-Discussed action steps for building community support.
-Identified resources for training and technical assistance to implement the Guidelines.
Presenter:
Linda J. Frazier, B.S, M.A., RN, MCHES
Principal Consultant, Advocate for Human Potential, Inc.
Posted 4/26/2023 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the Spring 2023 Data Learning Collaborative for all RCORP grant recipients. These sessions built the foundation for data learning, and we dove into data-related topics during each month’s skills-building session.
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 3/9/2022 (updated 3/27/2024)
A disproportionate number of people in jails have substance use disorders (SUDs).1 Incarceration provides a valuable opportunity for identifying SUD and addressing withdrawal.* Within the first few hours and days of detainment, individuals who have suddenly stopped using alcohol, opioids, or other drugs may experience withdrawal symptoms, particularly when they have used the substances heavily or long-term. Without its identification and timely subsequent medical attention, withdrawal can lead to serious injury or death. Deaths from withdrawal are preventable, and jail administrators have a pressing responsibility to establish and implement withdrawal policy and protocols that will save lives and ensure legal compliance. This brief describes the scope of the challenge, provides an overview of constitutional rights and key legislation related to substance use withdrawal, and outlines steps for creating a comprehensive response to SUD.
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.